Ram Suresh
About Ram Suresh
Ram Suresh is the Vice President, Therapy Area Head, Oncology, Global Biometric Sciences at Bristol-Myers Squibb, with extensive experience in leading statistics and programming departments in major pharmaceutical companies.
Company
Ram Suresh currently works at Bristol-myers Squibb as Vice President, Therapy Area Head, Oncology, Global Biometric Sciences. His work involves leading statistical and programming efforts to support oncology therapeutic areas within the company, located in New Jersey, United States.
Title
Ram Suresh holds the title of Vice President, Therapy Area Head, Oncology, Global Biometric Sciences at Bristol-myers Squibb.
Education and Expertise
Ram Suresh earned his Doctorates, Doctor of Philosophy in Statistics and Philosophy from the University of Cincinnati, Ohio, studying there from 1987 to 1993. His research interests include Adaptive Designs and Bayesian Methods in Drug Development. He is an expert in implementing novel statistical designs in drug development and has extensive experience in leading statistical and programming departments.
Career Background
Before joining Bristol-myers Squibb, Ram Suresh has held several senior positions at major pharmaceutical companies. He worked at Novartis as Vice President, Statistics in 2015 in Basel, Switzerland. Prior to that, he was Vice President, Oncology Statistics and Programming at Gsk from 2011 to 2015 in Hayes, United Kingdom. He also served as Vice President, Late Development Statistics at Merck from 2009 to 2011 in Kenilworth, New Jersey, and Head, Late Development Statistics at Schering-plough Research Institute from 2006 to 2009 in the United States.
Professional Contributions
Ram Suresh has actively contributed to the pharmaceutical and biostatistics community through various roles. He served in the Program Committee of the FDA/Industry Workshop and participated in the PhRMA QT Statistics Expert Team. Additionally, he is a member of the Executive Committee of the Biopharmaceutical Section of the American Statistical Association (ASA). He has contributed to many regulatory submissions and product approvals in multiple therapeutic areas.